加载中
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
常规交易时段
US$1.45
−US$0.11 · -7.05%
盘中时间采用ET。市场数据可能有所延迟。
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
日内区间
当前US$1.45
52周区间
当前US$1.45
盘中时间采用ET。市场数据可能有所延迟。
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
日内区间
当前US$1.45
52周区间
当前US$1.45
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 36.31万 USD | 2780 USD | 4220 USD | 805 USD | 115.96万 USD |
| 毛利 | −36.31万 USD | −2780 USD | −4220 USD | −805 USD | −115.96万 USD |
| 研究与开发 | 163.61亿 USD | 283.63万 USD | 321.69万 USD | 329.14万 USD | 217.42万 USD |
| 销售、一般及管理费用 | 123.45亿 USD | 397.48万 USD | 112.06万 USD | 115.37万 USD | 150.35万 USD |
| 营业费用 | 2834.26万 USD | 681.11万 USD | 434.26万 USD | 444.63万 USD | 367.77万 USD |
| 利息收入 | 249 USD | — | — | — | — |
| 利息支出 | — | 205.18万 USD | 344.89万 USD | 180.84万 USD | 258.29万 USD |
| 折旧和摊销 | 36.31万 USD | 2780 USD | 4220 USD | 805 USD | 805 USD |
| 营业利润 | −2870.57万 USD | −681.38万 USD | −434.26万 USD | −444.63万 USD | −483.74万 USD |
| 净利润 | −2875.38万 USD | −888.29万 USD | −779.16万 USD | −625.47万 USD | −742.02万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI70.32万0.00%2.3万亿 USD0.03%US$380.42-0.30%
Vanguard Extended Market ETFVXF61.1万0.00%954亿 USD0.05%US$231.62-0.82%
iShares Micro-Cap ETFIWC17.52万0.01%13.17亿 USD0.60%US$179.78-1.04%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM7万0.06%1.16亿 USD0.73%US$15.71-0.87%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
